tiprankstipranks
Trending News
More News >
Portage Biotech Inc (PRTG)
NASDAQ:PRTG
US Market

Portage Biotech Inc (PRTG) AI Stock Analysis

Compare
123 Followers

Top Page

PR

Portage Biotech Inc

(NASDAQ:PRTG)

Rating:48Neutral
Price Target:
Portage Biotech Inc. exhibits significant financial weaknesses, such as no revenue and persistent losses, which heavily weigh down the overall score. Despite strong technical indicators suggesting bullish momentum, the poor valuation metrics and financial performance hinder the stock's attractiveness. The absence of earnings call data or notable corporate events leaves these factors out of consideration.

Portage Biotech Inc (PRTG) vs. SPDR S&P 500 ETF (SPY)

Portage Biotech Inc Business Overview & Revenue Model

Company DescriptionPortage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
How the Company Makes MoneyPortage Biotech Inc. generates revenue primarily through the development and commercialization of its proprietary cancer immunotherapy products. The company's revenue streams include licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies. These partnerships often involve milestone payments, royalties on sales, and joint development efforts that leverage Portage's innovative technologies. Additionally, the company may receive funding from grants and research collaborations that support the advancement of its therapeutic pipeline. Portage's focus on cutting-edge oncology solutions positions it to capitalize on the growing demand for effective cancer treatments, contributing to its financial performance.

Portage Biotech Inc Financial Statement Overview

Summary
Portage Biotech Inc. faces significant financial challenges, with no revenue generation, persistent losses, and negative cash flows. Although the company maintains low leverage, its declining equity and asset base raise concerns about long-term sustainability. The financial outlook remains bleak without strategic improvements or revenue generation.
Income Statement
15
Very Negative
Portage Biotech Inc. has reported zero revenue over the periods, indicating no sales activity. The company consistently incurs high net losses, resulting in negative net profit margins. EBIT and EBITDA margins are also negative, reflecting operational challenges in generating profits.
Balance Sheet
30
Negative
The company's debt-to-equity ratio is low, indicating minimal leverage. However, the declining stockholders' equity and total assets suggest weakening financial stability. The equity ratio remains positive but is trending downward, highlighting potential risks in asset management.
Cash Flow
20
Very Negative
Operating cash flow remains negative, highlighting inefficiencies in generating cash from core operations. Free cash flow is negative, showing continued cash outflows. There is no observable growth in free cash flow, raising concerns about liquidity.
BreakdownTTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-28.00K-54.00K-1.00K0.000.000.00
EBITDA-78.04M-18.20M-16.62M-15.65M-14.19M-5.95M
Net Income-67.28M-75.34M-104.61M-16.87M-15.83M-5.33M
Balance Sheet
Total Assets2.71M7.78M99.13M194.66M174.86M173.17M
Cash, Cash Equivalents and Short-Term Investments1.76M5.03M10.54M23.35M2.77M3.22M
Total Debt28.00K47.00K0.000.00150.00K3.66M
Total Liabilities2.01M4.45M23.73M29.23M27.26M27.53M
Stockholders Equity1.40M4.02M76.05M121.20M101.45M96.53M
Cash Flow
Free Cash Flow-9.79M-14.30M-12.08M-6.76M-3.28M-3.71M
Operating Cash Flow-9.79M-14.30M-12.07M-6.76M-4.28M-3.71M
Investing Cash Flow2.81M2.81M-617.00K0.00-860.00K0.00
Financing Cash Flow5.31M5.97M-117.00K27.35M4.76M700.00K

Portage Biotech Inc Technical Analysis

Technical Analysis Sentiment
Negative
Last Price5.84
Price Trends
50DMA
7.82
Negative
100DMA
6.57
Negative
200DMA
5.91
Negative
Market Momentum
MACD
-0.58
Negative
RSI
41.03
Neutral
STOCH
32.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTG, the sentiment is Negative. The current price of 5.84 is below the 20-day moving average (MA) of 6.43, below the 50-day MA of 7.82, and below the 200-day MA of 5.91, indicating a bearish trend. The MACD of -0.58 indicates Negative momentum. The RSI at 41.03 is Neutral, neither overbought nor oversold. The STOCH value of 32.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRTG.

Portage Biotech Inc Risk Analysis

Portage Biotech Inc disclosed 28 risk factors in its most recent earnings report. Portage Biotech Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We rely on information technology and security systems and any damage, interruption or compromise of our information technology and security systems or data could disrupt and harm our business. Q1, 2023
2.
Any actual or perceived failure by us to comply with government or other obligations related to privacy or data protection could adversely affect our business. Q1, 2023

Portage Biotech Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$14.45M0.79-162.42%-82.24%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
49
Neutral
$7.84M-72.70%5.05%26.13%
49
Neutral
$9.46M-451.34%-57.84%
48
Neutral
$13.42M-194.84%48.91%
46
Neutral
$8.14M-80.71%-2.06%49.73%
43
Neutral
$41.10M-27.00%1904.43%93.72%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRTG
Portage Biotech Inc
5.84
2.82
93.38%
EKSO
EKSO BIONICS
3.49
-12.56
-78.26%
BMRA
Biomerica
3.23
-0.26
-7.45%
ABVC
ABVC BioPharma
3.10
2.36
318.92%
ADXN
Addex Therapeutics
9.13
0.46
5.31%
DWTX
Dogwood Therapeutics
4.83
-0.95
-16.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 29, 2025